{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:34:48Z","timestamp":1771662888105,"version":"3.50.1"},"reference-count":34,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,15]]},"DOI":"10.2169\/internalmedicine.3954-24","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T22:12:46Z","timestamp":1720649566000},"page":"543-549","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Denosumab and Bisphosphonates on Glucocorticoid-induced Osteoporosis in Patients with Neuroimmunological Disorders"],"prefix":"10.2169","volume":"64","author":[{"given":"Hideo","family":"Handa","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Ogaya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Niibe","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 10: 493-506, 2014.","DOI":"10.1038\/nrneurol.2014.141"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers 5: 30, 2019.","DOI":"10.1038\/s41572-019-0079-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Dis Primers 4: 31, 2018.","DOI":"10.1038\/s41572-018-0027-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69: 1095-1110, 2017.","DOI":"10.1002\/acr.23279"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 34: 341-356, viii-ix, 2005.","DOI":"10.1016\/j.ecl.2005.01.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kwon YN, Im SY, Park YS, et al. Bone health in neuromyelitis optica: bone mineral density and fractures. Mult Scler Relat Disord 42: 102080, 2020.","DOI":"10.1016\/j.msard.2020.102080"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Yeh JH, Chen HJ, Chen YK, Chiu HC, Kao CH. Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology 83: 1075-1079, 2014.","DOI":"10.1212\/WNL.0000000000000804"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kim SW, Kim EH, Lee J, Choi YC, Kim SM, Shin HY. Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study. Sci Rep 9: 9131, 2019.","DOI":"10.1038\/s41598-019-45591-4"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open 1: e000014, 2015.","DOI":"10.1136\/rmdopen-2014-000014"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56: 208-214, 2007.","DOI":"10.1002\/art.22294"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Amiche MA, Abtahi S, Driessen JHM, et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13: 30, 2018.","DOI":"10.1007\/s11657-018-0424-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Soen S, Kaku M, Okubo N, Onishi Y, Saito K, Kobayashi M. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan. J Bone Miner Metab 40: 636-647, 2022.","DOI":"10.1007\/s00774-022-01325-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore) 96: e6983, 2017.","DOI":"10.1097\/MD.0000000000006983"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 6: 82-88, 2010.","DOI":"10.1038\/nrrheum.2009.259"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bone HG, Wagman RB. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM Trial and open-label extension. Lancet Diabetes Endocrinol 5: 513-523, 2017.","DOI":"10.1016\/S2213-8587(17)30138-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028-2039, 2007.","DOI":"10.1056\/NEJMoa071408"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Saag KG, Pannacciulli N, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71: 1174-1184, 2019.","DOI":"10.1002\/art.40874"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75: 222-228, 2015.","DOI":"10.1016\/j.bone.2015.03.002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Iseri K, Iyoda M, Watanabe M, et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLOS ONE 13: e0193846, 2018.","DOI":"10.1371\/journal.pone.0193846"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Mok CC, Ho LY, Leung SMT, Cheung HN, Chen SPL, Ma KM. Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial. Bone 146: 115902, 2021.","DOI":"10.1016\/j.bone.2021.115902"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tanaka Y, Soen S, Hirata S, et al. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab 42: 143-154, 2024.","DOI":"10.1007\/s00774-024-01502-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD. Understanding and managing corticosteroid-induced osteoporosis. Open Access Rheumatol 13: 177-190, 2021.","DOI":"10.2147\/OARRR.S282606"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777-787, 2002.","DOI":"10.1007\/s001980200108"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19: 893-899, 2004.","DOI":"10.1359\/JBMR.040134"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Paggiosi MA, Peel NFA, Eastell R. The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int 26: 1773-1780, 2015.","DOI":"10.1007\/s00198-015-3078-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lian KC, Lang TF, Keyak JH, et al. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int 16: 642-650, 2005.","DOI":"10.1007\/s00198-004-1736-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Graeff C, Marin F, Petto H, et al. High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 52: 568-577, 2013.","DOI":"10.1016\/j.bone.2012.10.036"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLOS ONE 6: e25900, 2011.","DOI":"10.1371\/journal.pone.0025900"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM, Guo J. Loss of wnt\/\u03b2-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res 27: 2344-2358, 2012.","DOI":"10.1002\/jbmr.1694"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPAR\u03b32. J Cell Biochem 74: 357-371, 1999.","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.3.CO;2-Z"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Jilka RL, Noble B, Weinstein RS. Osteocyte apoptosis. Bone 54: 264-271, 2013.","DOI":"10.1016\/j.bone.2012.11.038"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48: 677-692, 2011.","DOI":"10.1016\/j.bone.2010.11.020"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Oka H, Yoshimura N, Kinoshita H, Saiga A, Kawaguchi H, Nakamura K. Decreased activities of daily living and associations with bone loss among aged residents in a rural Japanese community: the Miyama Study. J Bone Miner Metab 24: 307-313, 2006.","DOI":"10.1007\/s00774-006-0688-x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D<sub>3<\/sub> supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125: 961-968, 1996.","DOI":"10.7326\/0003-4819-125-12-199612150-00004"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3954-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:31:27Z","timestamp":1739590287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3954-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3954-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"article-number":"3954-24"}}